With its fourth transnational call (non-cofunded by the EC), ERA PerMed fosters research and innovation activities that build close linkages between clinical research, computer science/medical informatics and research on ethical, legal and social aspects (ELSA) in the field of Personalised Medicine (PM). This implies a wide range of multidisciplinary activities brought together by different stakeholders from academia, clinical/public health research and private partners such assmall and medium-sized enterprises (SMEs), policy makers, regulatory/health technology assessment (HTA) agencies and patients/patient organisations.
As Personalised Medicine is non-disease-specific, but rather an overall approach that can be adopted and adapted to a multiplicity of medical conditions, research projects in every disease entity are encouraged.
ERA PerMed3 is an ERA-NET Cofund, supported by 32 partners from 23 countries and cofunded by the European Commission.
This call is opened and supported simultaneously by 30 funding organisations worldwide, including the following
three LAC institutions :
Brazilian National Council of State Funding Agencies – CONFAP, Brazil
Agencia Nacional de Investigación y Desarrollo (ANID), Chile
National Secretariat for Science, Technology and Innovation of Panama (SENACYT), Panama.
The others are from Austria, Belgium, Croatia, Denmark, Egypt, Estonia, Finland, France, Germany, Hungary, Israel, Italy, Latvia, Luxembourg, Norway, Poland, Romania, Spain, Sweden and Turkey.
Eligibility criteria (among others):
• Only transnational projects will be funded.
• Each consortium submitting a proposal must involve at least three partners eligible for funding from three different countries whose funders participate in the call (see list above). All three legal entities must be independent of each other.
• At least two partners out of the minimum three eligible project partners of the consortium must be from two different EU Member States or Associated Countries.
Deadline for pre-proposal submission: 4 March 2021 at 17:00 (CET)
Deadline for full-proposal submission: 17 June 2021 at 17:00 (CEST)
- FAPDF (Distrito Federal)
- FAPEAM (Amazonas)
- FAPEPI (Piauí)
- FAPERGS (Rio Grande do Sul)
- FAPERJ (Rio de Janeiro)
- FAPES (Espírito Santo)
- FAPESB (Bahia)
- FAPESP (São Paulo)
- FUNCAP (Ceará)
- FAPEMA (Maranhão)
Definition of Personalised Medicine: “Personalised Medicine refers to a medical model using characterisation of individuals’ phenotypes and genotypes (e.g. molecular profiling, medical imaging, lifestyle data) for tailoring the right therapeutic strategy for the right person at the right time, and/or to determine the predisposition to disease and/or to deliver timely and targeted prevention.”